• Discovery of Pirtobrutinib Recognised with Plaque

    Read more
  • Redx to Present Poster on the Potential of RXC008 in Crohn’s Disease at the Inflammatory Bowel Disease Nordic Conference

    Read more
  • RXC004 Phase 2 Combination Arms to Open Enrolment

    Read more
  • Redx to Present at Jefferies London

    Read more
  • Redx Presents Encouraging RXC004 Preclinical Data at the AACR Annual Meeting in Combination with Clinically Relevant Standard of Care Regimens

    Read more
  • Redx Announces Collaboration with the Garvan Institute of Medical Research

    Read more
  • Redx Nominates GI-targeted ROCK Inhibitor, RXC008, as Clinical Development Candidate

    Read more
  • Redx to Present at the American Association for Cancer Research (AACR) Annual Meeting

    Read more
  • Redx Presents Encouraging Phase 1 Safety Data for RXC007

    Read more
  • Board Committee Changes

    Read more